Fever-Tree today (25 January) reported a 6% rise in annual revenues, a level of growth below the guidance the UK mixers business set out in September.
In a trading update ahead of the publication of Fever-Tree’s full financial results in March, the company posted 2023 revenue of £364.4m ($464.1m), up 6% on a reported basis and at constant currencies.
Go deeper with GlobalData
However, Australia and markets in Europe, “most notably” Germany, weighed on Fever-Tree’s top line, which compared to the group’s September guidance of £380-390m.
Fever-Tree did not disclose full profit figures but said it expects to record adjusted EBITDA of “circa £30m”. In September, the company forecast annual adjusted EBITDA of £30-36m. The consensus forecast among City analysts was £32m.
The group said its UK revenue was “ahead of guidance, reflecting good trading in Q4, particularly in the on-trade”.
See Also:
It reported a 22% rise in revenue in the US, a market that became the company’s “largest region” in 2023, CEO Tim Warrillow said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn Europe, revenue generated from the Fever-Tree brand grew 6% but the company said its growth “was impacted by subdued consumer sentiment in several markets”, especially Germany.
Meanwhile, revenue from the company’s Rest of the World reporting region dropped 14% as the group changed its set-up in Australia.
Fever-Tree said the division was “in growth”, excluding Australia, where the move to a “new subsidiary set-up” led to a one-off “inventory buy-back” and hit sales.
Warrillow said: “The Fever-Tree brand has performed well in 2023, growing our market share in all of our key markets, despite a challenging macroeconomic environment. Despite recession in Germany impacting our European performance and the one-off effect of the transition to our new subsidiary in Australia, we remain confident of driving good growth in those regions in 2024.”
He added: “Importantly, we have driven a significant increase in our EBITDA margin in the second half of the year and are confident that the operational efficiencies we have implemented, alongside a reduction in inflationary cost pressures, will drive a doubling of EBITDA in 2024 and provide a strong platform for profitable growth going forward.”
Shares in Fever-Tree were down 1.19% at 1,000p at 10:20 GMT.
In a note to clients, Stifel analyst Mark Irvine-Fortescue said: “A lower base and non-brand restructuring means 2024 guidance implies a circa 7% downgrade to consensus revenue and circa 6% to EBITDA. We are ‘buy’ rated because we think margin headwinds are reversing and Fever-Tree no longer has to ‘shoot the lights out’ in the US to justify high near-term valuation multiples.”
